文献速递消化系统肿瘤

PARERE研究:RAS/BRAF野生型ctDNA mCRC中帕尼单抗再治疗与瑞戈非尼的序贯比较

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.
PubMed 文献 · Ann Oncol · 2025-10-18

PARERE是一项开放标签、多中心、随机II期试验,在化疗难治且ctDNA为RAS/BRAF野生型的mCRC患者中比较帕尼单抗再治疗序贯瑞戈非尼与相反顺序的疗效。主要终点OS在两组间无差异(中位OS 11.7 vs 11.6个月,HR 1.13,P=0.441),但帕尼单抗再治疗与更高的ORR、DCR和更长的PFS相关。

要点

  • ctDNA RAS/BRAF野生型化疗难治mCRC中,帕尼单抗再治疗序贯瑞戈非尼与相反顺序的OS无差异。
  • 帕尼单抗再治疗的ORR、DCR和PFS均优于瑞戈非尼,与序贯顺序无关。
  • 抗EGFR再治疗可作为ctDNA无获得性耐药突变的RAS/BRAF野生型mCRC的连续治疗选择。

核心结论

  • 在化疗难治且ctDNA为RAS/BRAF野生型的mCRC患者中,帕尼单抗再治疗与瑞戈非尼的序贯顺序不影响OS。
  • 抗EGFR再治疗应被视为ctDNA无获得性耐药改变的RAS/BRAF野生型mCRC患者连续治疗中的一个选择。

研究设计与样本

  • PARERE(NCT04787341)为开放标签、多中心、随机II期试验,1:1随机分配至帕尼单抗再治疗序贯瑞戈非尼(A组)或相反顺序(B组)。
  • 入组患者为化疗难治的RAS/BRAF野生型mCRC,既往一线含抗EGFR方案获益后接受至少一线不含抗EGFR的治疗,且前瞻性ctDNA检测确认无RAS/BRAF突变。
  • 共428例患者进行分子筛查,213例RAS/BRAF ctDNA野生型患者被随机分配(A组106例,B组107例)。
  • 主要终点为总生存期(OS)。

主要发现

  • 中位随访31.9个月,B组和A组的中位OS分别为11.7个月和11.6个月(HR 1.13,85%CI 0.90-1.41,P=0.441)。
  • 帕尼单抗再治疗的首次ORR为16% vs 2%(P=0.003),第二次ORR为18% vs 0%(P=0.013)。
  • 帕尼单抗再治疗的首次DCR为61% vs 36%(P<0.001),第二次DCR为62% vs 38%(P=0.003)。
  • 帕尼单抗再治疗的首次PFS为4.2 vs 2.4个月(P=0.103),第二次PFS为3.9 vs 2.7个月(P=0.019),均优于瑞戈非尼,与治疗顺序无关。

临床怎么用

  • 对化疗难治且ctDNA确认RAS/BRAF野生型的mCRC患者,可考虑抗EGFR再治疗作为连续治疗策略的一部分。
  • 帕尼单抗再治疗在ORR、DCR和PFS方面优于瑞戈非尼,但OS无差异,序贯顺序可根据临床情况选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Re-treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies offers a promising approach to extend the continuum of care of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) with no mutations of resistance in their circulating tumor DNA (ctDNA) at the time of treatment re-exposure. PATIENTS AND METHODS: PARERE (NCT04787341) is an open-label, multicenter, randomized phase II trial investigating the optimal sequencing of panitumumab and regorafenib in chemorefractory RAS and BRAF wt mCRC patients, who previously derived benefit from first-line anti-EGFR-containing regimens, then received at least one intervening anti-EGFR-free line of treatment, and were prospectively selected for the absence of RAS and BRAF mutations in their ctDNA. Eligible patients were randomly assigned 1 : 1 to receive anti-EGFR re-treatment with panitumumab followed by regorafenib after progression (arm A) versus the reverse sequence (arm B). The primary endpoint was overall survival (OS). RESULTS: Between December 2020 and December 2024, 428 patients underwent molecular screening, and 213 with RAS/BRAF ctDNA wt were randomized (arm A/B = 106/107). At a median follow-up of 31.9 months, no difference in terms of OS was observed between treatment arms, with a median OS of 11.7 and 11.6 months in arms B and A, respectively (hazard ratio 1.13, 85% confidence interval 0.90-1.41, P = 0.441). However, re-treatment with panitumumab was associated with higher objective response rate (ORR; first ORR: 16% versus 2%, P = 0.003; second ORR: 18% versus 0%, P = 0.013) and disease control rate (DCR; first DCR: 61% versus 36%, P < 0.001; second DCR: 62% versus 38%, P = 0.003), and longer progression-free survival (PFS; first PFS: 4.2 versus 2.4 months, P = 0.103; second PFS: 3.9 versus 2.7 months, P = 0.019) than regorafenib, regardless of the sequence of the study treatments. CONCLUSIONS: Anti-EGFR re-treatment should be regarded as an option in the continuum of care of chemorefractory mCRC patients with RAS and BRAF wt tumors, with no alterations of acquired resistance in their ctDNA.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ciracì P, Germani MM, Pietrantonio F, et al. Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO. Ann Oncol. 2025. PMID: 41115464. doi:10.1016/j.annonc.2025.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。